Jeff Ryckman· @jryckman3 · X·· 12 小时前评分60
正文 · 原文
KEYNOTE-975: adding pembro to definitive CRT didn't improve EFS in CPS>=10 esophageal/GEJ cancer. HR 0.97 (95% CI 0.77-1.23). Hierarchy stopped there; OS wasn't formally tested. Another reason not to assume IO helps every CRT backbone. #ESMO26 #radonc https://t.co/JCWWmcCZHS https://t.co/SCdkZqxsjS
热度 0 · 0 赞 · 0 回复 · 0 转发
会议摘要
NCT04210115NCT04210115按 - **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) 对上
- **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)读摘要原文 →来源：Jeff Ryckman · x.com